Your browser doesn't support javascript.
loading
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Bernard-Tessier, A; Baldini, C; Martin, Patricia; Champiat, Stéphane; Hollebecque, Antoine; Postel-Vinay, Sophie; Varga, Andrea; Bahleda, Rastilav; Gazzah, Anas; Michot, Jean-Marie; Ribrag, Vincent; Armand, Jean-Pierre; Marabelle, Aurélien; Soria, Jean-Charles; Massard, C.
Afiliação
  • Bernard-Tessier A; Université Paris-Saclay, Villejuif, F-94805, France.
  • Baldini C; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Martin P; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Champiat S; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Hollebecque A; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Postel-Vinay S; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Varga A; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Bahleda R; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Gazzah A; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Michot JM; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Ribrag V; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France; Université Paris-Saclay, Villejuif, F-94805, France; INSERM, U1170, Gustave Roussy, Villejuif, F-94805, France.
  • Armand JP; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Marabelle A; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Soria JC; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France.
  • Massard C; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, F-94805, France. Electronic address: christophe.massard@gustaveroussy.fr.
Eur J Cancer ; 101: 160-164, 2018 09.
Article em En | MEDLINE | ID: mdl-30071444
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Anticorpos Monoclonais / Neoplasias Tipo de estudo: Guideline / Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Anticorpos Monoclonais / Neoplasias Tipo de estudo: Guideline / Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article